2157.HK

Lepu Biopharma Co Ltd [2157.HK] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

2157.HK Stock Summary

Top 10 Correlated ETFs

2157.HK

Top 10 Correlated Stocks

2157.HK

In the News

2157.HK Financial details

Company Rating
-
Market Cap
6.15B
Income
-833.64M
Revenue
268.7M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
429
Optionable
No
Shortable
Yes
Earnings
23 Aug 2024
P/E
-8.2
Forward P/E
-
PEG
4.94
P/S
355.03
P/B
6.27
P/C
-
P/FCF
-9.35
Quick Ratio
0.79
Current Ratio
0.96
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.51
EPS next Y
-
EPS next Q
-
EPS this Y
-31.15%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-55.33%
EPS Q/Q
-180.66%
-
-
-
-
SMA20
22.25%
SMA50
46.13%
SMA100
47.62%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-79%
ROC
-0.42%
Gross Margin
87%
Oper. Margin
-4524%
Profit Margin
-4425%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.63-6.99
52W High
-16%
52W Low
+152%
RSI
68.56
Rel Volume
23.64
Avg Volume
1.34M
Volume
31.69M
Perf Week
27.27%
Perf Month
57.5%
Perf Quarter
64.17%
Perf Half Y
62.06%
-
-
-
-
Beta
-0.105
-
-
Volatility
0.28%, 0.5%
Prev Close
9.57%
Price
5.04
Change
18.03%

Something similar

Top by Market Cap
ABEC.DE
V
FXAIX
3V64.DE
CMC.DE
Top Correlated ETFs
GLDA.L
SGBX.L
GLDW.L
SOYB.L
GBS.L
Top Correlated Stocks
1801.HK
9926.HK
9928.HK
0392.HK
0667.HK
Similar Market Cap
002990.SZ
8374.TW
002706.SZ
8033.TW
SECARE.ST

Company Profile

Healthcare Biotechnology
  • Volume Average 1.34M
  • Market Capitalization 6.15B
  • Employee 429
  • CEO Dr. Ziye Sui M.D., Ph.D.
  • Headquarters Shanghai,CN
  • IPO Date 2022-02-23
  • Website https://www.lepubiopharma.com

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.